New data further define role of PD-L1 status, immunotherapy in metastatic breast cancer
BARCELONA – PD-L1 status in mTNBC or HER2+ breast cancer appears to identify distinct disease entities with varying likelihood of benefit from...
USPSTF recommendations on risk assessment, genetic counseling, and genetic testing for BRCA-related cancer
They recommend using screening tools focusing on family history that primary care physicians can utilize to determine who should be referred for...
Trastuzumab benefit lasts long-term in HER2+ breast cancer
The benefit of trastuzumab was greater among patients with HR+ disease than those with HR– disease until the 5-year timepoint, after which HR...
Gene recurrence score helps predict successful combination therapy for early breast cancer
Women with a high recurrence score on a 21-gene breast cancer assay fared better with chemoendocrine therapy than expected with endocrine therapy...
Mortality after breast cancer diagnosis found higher for men
Male patients had 19% higher 5-year mortality than their female counterparts even after confounders were taken into account.
FDA issues warning for CDK 4/6 inhibitors
In a review of trials and postmarket safety databases, the FDA found there were reports of serious cases of pneumonitis, including fatalities,...
Prognostic significance of primary tumor location in breast cancer: An Analysis of the National Cancer Database (NCDB)
Developing Community Partnerships to Improve Breast Cancer Survivorship for Young Women
Oncologists agree with AI treatment decisions about half the time
In the first study of its kind, involving 10 Chinese oncologists and 1,977 patients with complex breast cancer, treatment recommendations from the...
Cancer survivors face more age-related deficits
Cancer survivors are more likely to experience age-related health deficits and increased mortality, compared with people without a history of...